Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| TRVITrevi Therapeutics Inc | $95.0M | 8.7% | |
| PRAXPraxis Precision Medicines | $90.8M | 8.3% | −20.0% |
| ERASErasca Inc | $75.6M | 6.9% | −66.0% |
| AVBPArrivent BioPharma Inc | $58.4M | 5.3% | +89.9% |
| ABVXAbivax SA - ADR | $55.3M | 5.0% | +73.2% |
| TNGXTango Therapeutics Inc | $43.1M | 3.9% | −36.0% |
| CRVSCorvus Pharmaceuticals Inc | $41.9M | 3.8% | |
| DRUGBright Minds Biosciences Inc | $39.1M | 3.6% | |
| Sinovac Biotech Ltd.CUSIP P8696W104 | $38.2M | 3.5% | |
| TENXTenax Therapeutics Inc | $36.4M | 3.3% | +1100.0% |
| ACRSAclaris Therapeutics, Inc. | $35.4M | 3.2% | |
| DYNDyne Therapeutics Inc | $34.6M | 3.2% | |
| DNTHDianthus Therapeutics Inc | $34.5M | 3.2% | |
| ANROAlto Neuroscience Inc | $31.9M | 2.9% | +16.7% |
| DBVTDBV Technologies SA | $30.3M | 2.8% | −30.8% |
| SABSSAB Biotherapeutics Inc | $28.5M | 2.6% | −36.1% |
| MLTXMoonlake Immunotherapeutics | $27.3M | 2.5% | +40.0% |
| LBRXLB Pharmaceuticals Inc | $26.0M | 2.4% | |
| NERVMinerva Neurosciences Inc | $24.0M | 2.2% | |
| DSGNDesign Therapeutics Inc | $23.3M | 2.1% | |
| ORICOric Pharmaceuticals Inc | $20.0M | 1.8% | |
| CAMPCAMP4 Therapeutics Corporation | $18.6M | 1.7% | |
| FTHFaeth Therapeutics Inc | $18.1M | 1.6% | |
| ACHVAchieve Life Sciences Inc. | $18.0M | 1.6% | New |
| CMPXCompass Therapeutics Inc | $17.0M | 1.6% | −18.7% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| TNGXTango Therapeutics Inc | June 30, 2025 | +510.5% | $43.1M |
| TRVITrevi Therapeutics Inc | September 30, 2024 | +458.4% | $95.0M |
| TENXTenax Therapeutics Inc | September 30, 2024 | +320.5% | $36.4M |
| CRVSCorvus Pharmaceuticals Inc | September 30, 2024 | +183.0% | $41.9M |
| DNTHDianthus Therapeutics Inc | September 30, 2025 | +147.7% | $34.5M |
| SRZNSurrozen Inc | March 31, 2025 | +122.6% | $6.7M |
| ACRSAclaris Therapeutics, Inc. | December 31, 2024 | +113.3% | $35.4M |
| LBRXLB Pharmaceuticals Inc | September 30, 2025 | +105.5% | $26.0M |
| DRUGBright Minds Biosciences Inc | December 31, 2024 | +94.9% | $39.1M |
| SABSSAB Biotherapeutics Inc | September 30, 2025 | +94.0% | $28.5M |
Sold off last quarter
- Terns Pharmaceuticals IncCUSIP 880881107 was $70.4M
- MANEVeradermics Inc was $18.9M
- COGTCogent Biosciences Inc was $16.3M
- Soleno Therapeutics IncCUSIP 834203309 was $9.9M
- VRDNViridian Therapeutics Inc was $3.3M
- CMPSCompass Pathway PLC was $1.1M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +9.2% | +14.8% |
| September 30, 2025 | +21.8% | +7.8% |
| June 30, 2025 | +19.8% | +10.5% |
| March 31, 2025 | +5.8% | −4.6% |
| December 31, 2024 | −9.8% | +2.1% |
| September 30, 2024 | +20.3% | +5.4% |
| June 30, 2024 | −8.1% | +4.0% |
| March 31, 2024 | +13.3% | +10.0% |
| March 31, 2023 | −19.1% | +7.0% |
| December 31, 2022 | +18.7% | +7.1% |
| September 30, 2022 | +19.6% | −5.3% |
| June 30, 2022 | −15.6% | −16.5% |
| March 31, 2022 | −14.0% | −4.9% |
| December 31, 2021 | −15.2% | +10.7% |
| September 30, 2021 | +5.4% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Vivo Capital, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1674712&type=13F-HR&dateb=&owner=include&count=40CIK 1674712
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1674712/000121390026089935/Filed August 14, 2026 · accession 0001213900-26-089935